HS
PTCT icon

HighVista Strategies’s PTC Therapeutics PTCT Stock Holding History

HighVista Strategies’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-13,237
Closed -$297K – 141
2023
Q3 		$297K Buy
+13,237
New +$492K 0.14% 131
2023
Q2 		– Sell
-16,535
Closed -$801K – 148
2023
Q1 		$801K Buy
+16,535
New +$756K 0.65% 48
2020
Q3 		– Sell
-8,198
Closed -$416K – 126
2020
Q2 		$416K Buy
+8,198
New +$403K 0.34% 54

Other funds holding PTCT

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HighVista Strategies's PTCT Position: Q4 2023 in Review

HighVista Strategies sold out of PTC Therapeutics (PTCT) in Q4 2023, closing a stake of 13,237 shares — an estimated $297K sold.

HighVista Strategies first reported a position in PTCT in Q2 2020 and held it in 3 quarters. The position peaked at $801K in Q1 2023. 172 funds tracked by Wall St. Rank hold PTCT as of Q4 2023.

  • HighVista Strategies reported no remaining PTC Therapeutics position as of Q4 2023 after selling out during the quarter.
  • HighVista Strategies sold 13,237 PTC Therapeutics shares in Q4 2023, an estimated $297K.
  • HighVista Strategies first reported a position in PTC Therapeutics in Q2 2020 and held it in 3 quarters.
  • HighVista Strategies's PTC Therapeutics position peaked at $801K in Q1 2023.
  • 172 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2023.

Based on HighVista Strategies's 13F filing for Q4 2023, filed 14 Feb 2024.